BR112022007047A2 - Tratamento de doença hepática gordurosa não alcoólica - Google Patents
Tratamento de doença hepática gordurosa não alcoólicaInfo
- Publication number
- BR112022007047A2 BR112022007047A2 BR112022007047A BR112022007047A BR112022007047A2 BR 112022007047 A2 BR112022007047 A2 BR 112022007047A2 BR 112022007047 A BR112022007047 A BR 112022007047A BR 112022007047 A BR112022007047 A BR 112022007047A BR 112022007047 A2 BR112022007047 A2 BR 112022007047A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- treatment
- liver disease
- fatty liver
- alcoholic fatty
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 3
- 210000005229 liver cell Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000007863 steatosis Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
TRATAMENTO DE DOENÇA HEPÁTICA GORDUROSA NÃO ALCOÓLICA. A presente invenção refere-se ao peptídeo da SEQUÊNCIA ID Nº: 1 (WKDEAGKPLVK) que atua como mediador de alterações nas principais atividades de biomarcadores associadas com a NASH (Tabela 1) e que o peptídeo é capaz de penetrar as células hepáticas HepG2 em um ensaio de penetração de células hepáticas (Figura 1). Além disso, é demostrado que o tratamento com pep_260 (SEQ ID 1) durante 44 dias alivia significativamente a esteatose macrovesicular em camundongos KKAy diabéticos obesos (Figura 2). Em um primeiro aspecto, a invenção refere-se ao uso de um peptídeo compreendendo a SEQUÊNCIA ID Nº: 1, ou uma variante funcional (ou terapeuticamente eficaz) ou fragmento funcional da SEQUÊNCIA ID Nº: 1 (daqui em diante "agente ativo de peptídeo" ou "peptídeo da invenção"), em um método para o tratamento ou prevenção de doença hepática gordurosa não alcoólica (NAFLD), em particular esteato-hepatite não alcoólica (NASH), em um mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19204536 | 2019-10-22 | ||
| PCT/EP2020/079836 WO2021078912A1 (en) | 2019-10-22 | 2020-10-22 | Treatment of non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007047A2 true BR112022007047A2 (pt) | 2022-07-05 |
Family
ID=68296374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007047A BR112022007047A2 (pt) | 2019-10-22 | 2020-10-22 | Tratamento de doença hepática gordurosa não alcoólica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240150403A1 (pt) |
| EP (1) | EP4041273A1 (pt) |
| JP (1) | JP2022553367A (pt) |
| KR (1) | KR20220109391A (pt) |
| CN (1) | CN114980913A (pt) |
| AU (1) | AU2020370733A1 (pt) |
| BR (1) | BR112022007047A2 (pt) |
| CA (1) | CA3154368A1 (pt) |
| MX (1) | MX2022004872A (pt) |
| WO (1) | WO2021078912A1 (pt) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| CN1832755A (zh) | 2003-05-23 | 2006-09-13 | 佩斯特卡生物医疗实验室公司 | 使用干扰素治疗严重急性呼吸综合征及其他病毒感染 |
| US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| US8105572B2 (en) | 2007-05-18 | 2012-01-31 | New York University | Method of treating tuberculosis with interferons |
| ES2522615T3 (es) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
| EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| ES2397890B1 (es) | 2011-03-25 | 2014-02-07 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas. |
| AU2017373651B2 (en) * | 2016-12-05 | 2022-03-10 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
-
2020
- 2020-10-22 JP JP2022523818A patent/JP2022553367A/ja active Pending
- 2020-10-22 WO PCT/EP2020/079836 patent/WO2021078912A1/en unknown
- 2020-10-22 BR BR112022007047A patent/BR112022007047A2/pt unknown
- 2020-10-22 KR KR1020227016657A patent/KR20220109391A/ko unknown
- 2020-10-22 MX MX2022004872A patent/MX2022004872A/es unknown
- 2020-10-22 US US17/768,356 patent/US20240150403A1/en active Pending
- 2020-10-22 CN CN202080089089.7A patent/CN114980913A/zh active Pending
- 2020-10-22 EP EP20803760.6A patent/EP4041273A1/en active Pending
- 2020-10-22 AU AU2020370733A patent/AU2020370733A1/en active Pending
- 2020-10-22 CA CA3154368A patent/CA3154368A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154368A1 (en) | 2021-04-29 |
| EP4041273A1 (en) | 2022-08-17 |
| JP2022553367A (ja) | 2022-12-22 |
| CN114980913A (zh) | 2022-08-30 |
| AU2020370733A1 (en) | 2022-05-05 |
| MX2022004872A (es) | 2022-05-13 |
| WO2021078912A1 (en) | 2021-04-29 |
| KR20220109391A (ko) | 2022-08-04 |
| US20240150403A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lowe | Cupping therapy: An analysis of the effects of suction on skin and the possible influence on human health | |
| BR112021021156A2 (pt) | Terapêuticos anticorpos totalmente humanos pós-tradução modificados | |
| BRPI0507039A8 (pt) | composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit | |
| BRPI0410963B8 (pt) | anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| Huhn et al. | Age-related loss of cardiac preconditioning: impact of protein kinase A | |
| BR112022020817A2 (pt) | Inibidores de kif18a para tratamento de doenças neoplásicas | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| BR112021021726A2 (pt) | Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doença hepática | |
| CL2020001504A1 (es) | Derivados de ácidos grasos para tratar la esteatohepatitis no alcohólica. | |
| BRPI0509876A (pt) | métodos para controlar a angiogênese e a proliferação de células | |
| BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
| BR112022007047A2 (pt) | Tratamento de doença hepática gordurosa não alcoólica | |
| BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo | |
| BR112021020525A2 (pt) | Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação | |
| CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112021024402A2 (pt) | Métodos e composições para tratamento de câncer com adjuvantes direcionados ao câncer | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
| BR112021023319A2 (pt) | Vetor viral | |
| BR112020027063A2 (pt) | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp | |
| Yong et al. | Electroacupuncture pretreatment attenuates brain injury in a mouse model of cardiac arrest and cardiopulmonary resuscitation via the AKT/eNOS pathway | |
| BR112019011370A2 (pt) | terapia de combinação | |
| BR112018015448A2 (pt) | conjugado anticorpo-fármaco, composição farmacêutica, métodos para liberar um agente ativo, para tratar uma doença, para inibir progressão de tumor e para inibir, diminuir ou eliminar a capacidade metastática de um tumor, e, kit. |